Clinical Applications of Urinary Cell-free DNA in Cancer: Current Insights and Promising Future

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2017 Dec 9

PMID 29218253

Citations 47

Authors

Tian Lu

Jinming Li

Affiliations

Soon will be listed here.

Abstract

Liquid biopsy is gaining significant attention as a tool for unveiling the molecular landscape of tumor and holds great promise for individualized medicine for cancer. Cell-free DNA serves as an extremely important component of liquid biopsy for cancer, and cell-free DNA in urine is even promising due to the remarkable advantage of urine as an ultra-noninvasive sample source over tissue and blood. Compared with the widely studied cell-free DNA in blood, less is known about the role of urinary cell-free DNA. Urinary cell-free DNA has the ability to give comprehensive and crucial information on cancer as it carries genetic messages from cells shedding directly into urine as well as transporting from circulation. As an indispensable component of liquid biopsy, urinary cell-free DNA is believed to have the potential of being a useful and ultra-noninvasive tool for cancer screening, diagnosis, prognosis, and monitoring of cancer progression and therapeutic effect. In this review, we provide the current insights into the clinical applications of urinary cell-free DNA in cancer. We also introduce the basic biological significance and some technical issues in the detection of urinary cell-free DNA.

Citing Articles

Diagnostic Value of Cross-priming Amplification Combined With CRISPR-Cas12b in Detecting Cell-free DNA in Tuberculous Pleural Effusion.

Peng L, Fang T, Dai L, Cai L Open Forum Infect Dis. 2024; 11(12):ofae674.

PMID: 39660021 PMC: 11630831. DOI: 10.1093/ofid/ofae674.

Insight into Fructose-to-Sucrose Ratio as the Potential Target of Urinalysis in Bladder Cancer.

Zhou D, Huang J, Zheng H, Liu Y, Zhu S, Du Y Metabolites. 2024; 14(6).

PMID: 38921479 PMC: 11205578. DOI: 10.3390/metabo14060345.

The Challenge to Stabilize, Extract and Analyze Urinary Cell-Free DNA (ucfDNA) during Clinical Routine.

Nel I, Munch C, Shamkeeva S, Heinemann M, Isermann B, Aktas B Diagnostics (Basel). 2023; 13(24).

PMID: 38132253 PMC: 10743081. DOI: 10.3390/diagnostics13243670.

Urinary mitochondrial DNA may be useful in diagnosing early diabetic nephropathy.

Xue L, Yang X, Song Y, Wang C, Zhou J, Liang H Exp Ther Med. 2023; 26(6):570.

PMID: 38023365 PMC: 10652235. DOI: 10.3892/etm.2023.12270.

Systems Biology in Cancer Diagnosis Integrating Omics Technologies and Artificial Intelligence to Support Physician Decision Making.

Fawaz A, Ferraresi A, Isidoro C J Pers Med. 2023; 13(11).

PMID: 38003905 PMC: 10672164. DOI: 10.3390/jpm13111590.

References

Song B, Jain S, Lin S, Chen Q, Block T, Song W . Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn. 2012; 14(2):112-9. PMC: 3349838. DOI: 10.1016/j.jmoldx.2011.12.003. View

Sardana G, Diamandis E . Biomarkers for the diagnosis of new and recurrent prostate cancer. Biomark Med. 2012; 6(5):587-96. DOI: 10.2217/bmm.12.72. View

Salvi S, Martignano F, Molinari C, Gurioli G, Calistri D, De Giorgi U . The potential use of urine cell free DNA as a marker for cancer. Expert Rev Mol Diagn. 2016; 16(12):1283-1290. DOI: 10.1080/14737159.2016.1254551. View

Casadio V, Calistri D, Tebaldi M, Bravaccini S, Gunelli R, Martorana G . Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol. 2012; 31(8):1744-50. DOI: 10.1016/j.urolonc.2012.07.013. View

Brisuda A, Pazourkova E, Soukup V, Horinek A, Hrbacek J, Capoun O . Urinary Cell-Free DNA Quantification as Non-Invasive Biomarker in Patients with Bladder Cancer. Urol Int. 2015; 96(1):25-31. DOI: 10.1159/000438828. View

Yokota M, Tatsumi N, Tsuda I, Takubo T, Hiyoshi M . DNA extraction from human urinary sediment. J Clin Lab Anal. 1998; 12(2):88-91. PMC: 6807926. View

Renard I, Joniau S, Van Cleynenbreugel B, Collette C, Naome C, Vlassenbroeck I . Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 2009; 58(1):96-104. DOI: 10.1016/j.eururo.2009.07.041. View

Tchekmedyian N, Mudad R, Blanco F, Raymond V, Garst J, Erlander M . Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. Lung Cancer. 2017; 108:22-28. DOI: 10.1016/j.lungcan.2017.02.010. View

Chan K, Leung S, Yeung S, Chan A, Lo Y . Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. Clin Cancer Res. 2008; 14(15):4809-13. DOI: 10.1158/1078-0432.CCR-08-1112. View

10.

He W, Bishop K . The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer. Expert Rev Mol Diagn. 2016; 16(8):839-52. DOI: 10.1080/14737159.2016.1197121. View

11.

Lin C, Huang W, Wei F, Su W, Wong D . Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. Expert Rev Mol Diagn. 2015; 15(11):1427-40. PMC: 4889428. DOI: 10.1586/14737159.2015.1094379. View

12.

Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp D . Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017; 23(14):3657-3666. PMC: 5511562. DOI: 10.1158/1078-0432.CCR-16-2592. View

13.

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

14.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

15.

Utting M, Werner W, Dahse R, Schubert J, Junker K . Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res. 2002; 8(1):35-40. View

16.

Xia Y, Huang C, Dittmar R, Du M, Wang Y, Liu H . Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget. 2016; 7(24):35818-35831. PMC: 5094965. DOI: 10.18632/oncotarget.9027. View

17.

Koide K, Sekizawa A, Iwasaki M, Matsuoka R, Honma S, Farina A . Fragmentation of cell-free fetal DNA in plasma and urine of pregnant women. Prenat Diagn. 2005; 25(7):604-7. DOI: 10.1002/pd.1213. View

18.

Reckamp K, Melnikova V, Karlovich C, Sequist L, Camidge D, Wakelee H . A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J Thorac Oncol. 2016; 11(10):1690-700. DOI: 10.1016/j.jtho.2016.05.035. View

19.

Tsui N, Jiang P, Chow K, Su X, Leung T, Sun H . High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. PLoS One. 2012; 7(10):e48319. PMC: 3485143. DOI: 10.1371/journal.pone.0048319. View

20.

Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, Van Damme P . Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis. 2011; 31(5):627-40. DOI: 10.1007/s10096-011-1358-z. View